The landmark approval of the first pill for postpartum depression offers an important new treatment for the 1 in 7 new mothers who experience the disorder.
Suicide is a leading cause of maternal mortality in the U.S.. And yet on its own, the new drug — promising as it is — isn’t enough. Consider that as many as half of women with postpartum depression go undiagnosed.
Nonetheless, the new pill is a remarkable breakthrough and one of several encouraging recent developments in women’s health — perhaps a sign that pharmaceutical companies are finally listening to the female half of the population.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.